Autolymphocyte therapy data

CLTX (Newton, Mass.) presented Phase III results from extended treatment of 150 patients who had completed an initial six-month therapy. The data, reported at the meeting of the Society for Biological Therapy in Napa, Calif., showed extended survival.

Median survival of the 150 patients was prolonged to 27 months, compared to a historical control of 6-13 months for patients receiving other therapies. Median duration of partial response (shrinkage of >50 percent, 12 patients) and complete response (100 percent tumor shrinkage, 7 patients) was 24 months. Some complete responses have lasted 36 months. ...